John A. Thompson

Appointments and Affiliations

University of Washington
School of Medicine
Professor, Appointed: 2004
Fred Hutchinson Cancer Research Center
Clinical Research Division
Professional Headshot of John A. Thompson

Mailing Address

Seattle Cancer Care Alliance
825 Eastlake Avenue E., G4830
Seattle, Washington 98109-1023
United States


Phone: (206) 288-2044
Fax: (206) 288-6210


M.D., University of Alabama, 1979.
B.A., Davidson College, 1973.

Research Interests

My clinical research interests focus on the immunotherapy of cancer with cytokines and activated lymphocytes. A partial listing of trials currently under my direction include:

I serve on the National Comprehensive Cancer Network Clinical Guidelines Committees for Melanoma and Occult Primary, the Southwest Oncology Group Melanoma and Lymphoma committees, and the Cytokine Working Group. I am a member of the American Joint Committee on Cancer working group for staging of melanoma. I am the current Secretary-Treasurer of the Washington State Medical Oncology Society.

Additional Experience

Alpha Omega Alpha, 1978
Recipient, Clinical Investigator Award (NCI), 1985-1988


American Association for Cancer Research
American Society of Clinical Oncology
Society for Biological Therapy
Southwest Oncology Group
Washington State Medical Oncology Society

Previous Positions

1993-2004, Associate Professor, University of Washington, School of Medicine, Medicine, Oncology
1988-1993, Assistant Professor, University of Washington, Oncology
1985-1988, Acting Assistant Professor, University of Washington, Oncology
1982-1985, Fellow, University of Washington, Oncology
1982-1982, Chief Medical Resident, Providence Medical Center
1979-1982, Intern and Resident, University of Washington, Internal Medicine


  • Phase II trial of chemo-immunotherapy for patients with stage IV melanoma - Principal Investigator
  • Phase III trial of therapy with Melacine vaccine and interferon versus interferon for patients with Stage III melanoma- Co-Investigator
  • Phase I/II trial of lymphocytes activated by stimulation with antibody to CD3 and CD28 plus interleukin-2 for patients with Stage IV renal cell carcinoma Principal Investigator
  • Randomized Phase III trial of total body irradiation, cyclophosphamide, etoposide, and autologous peripheral blood stem cell transplantation followed by interleukin-2 versus observation for patients with relapsed or refractory non-Hodgkin’s lymphoma, a SWOG trial Principal Investigator


Recent Publications

Thompson JA.  2016.  Major Changes in Systemic Therapy for Advanced Melanoma.. Journal of the National Comprehensive Cancer Network : JNCCN. 14(5 Suppl):638-40. Abstract
Coit DG, Thompson JA, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daniels GA, Daud A, Dimaio D, Fleming MD et al..  2014.  Melanoma, version 4.2014.. Journal of the National Comprehensive Cancer Network : JNCCN. 12(5):621-9. Abstract
Thompson JA.  2014.  Agents make "preferred list" in metastatic melanoma.. Journal of the National Comprehensive Cancer Network : JNCCN. 12(5 Suppl):785-7. Abstract